Smith & Nephew (NYSE:SNN – Get Free Report) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a note issued to investors on Wednesday,Briefing.com Automated Import reports.
Other analysts also recently issued research reports about the stock. Canaccord Genuity Group reaffirmed a “hold” rating and set a $27.00 price target on shares of Smith & Nephew in a report on Wednesday, February 26th. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $27.00.
View Our Latest Report on Smith & Nephew
Smith & Nephew Stock Performance
Institutional Investors Weigh In On Smith & Nephew
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. River Road Asset Management LLC raised its position in shares of Smith & Nephew by 64.0% during the fourth quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider’s stock valued at $49,947,000 after buying an additional 792,829 shares during the last quarter. J. Goldman & Co LP purchased a new position in shares of Smith & Nephew in the fourth quarter valued at $47,700,000. Brandes Investment Partners LP grew its holdings in shares of Smith & Nephew by 11.4% in the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider’s stock valued at $33,504,000 after purchasing an additional 138,994 shares in the last quarter. Clark Estates Inc. NY grew its holdings in shares of Smith & Nephew by 16.8% in the fourth quarter. Clark Estates Inc. NY now owns 800,000 shares of the medical equipment provider’s stock valued at $19,664,000 after purchasing an additional 115,000 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Smith & Nephew by 11.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 535,350 shares of the medical equipment provider’s stock valued at $13,159,000 after purchasing an additional 57,014 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.
About Smith & Nephew
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Stories
- Five stocks we like better than Smith & Nephew
- 5 discounted opportunities for dividend growth investors
- Rockwell Automation Poised to Gain From U.S. Tariffs & Onshoring
- How to buy stock: A step-by-step guide for beginners
- 3 Companies Buying Back Stock—Why It Matters
- What is MarketRank™? How to Use it
- Institutions Bought 3 Stocks Heavily in Q1 2025
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.